You are viewing: US Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The US Nuclear Medicine Market was valued at $4578.4 Million in 2025 and projected to reach to $9155.5 Million by 2030, representing a compound annual growth rate of 14.9%. The US nuclear medicine market is positioned for exceptional growth through 2030, driven by demographic shifts and increased disease prevalence requiring advanced diagnostic capabilities.

US Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Nuclear Medicine Market Trends and Insights

  • This growth trajectory reflects the US healthcare system's increasing adoption of diagnostic and therapeutic nuclear imaging technologies, driven by rising prevalence of chronic diseases and aging demographics.
  • The US market benefits from advanced healthcare infrastructure, high reimbursement rates, and significant investment in medical innovation. During the 2025–2030 forecast period, the US nuclear medicine sector will be propelled by technological advancements in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) systems.
  • The US regulatory environment, supported by FDA approvals and clinical evidence, continues to expand the therapeutic applications of radiopharmaceuticals.
  • Healthcare providers across the US are increasingly integrating hybrid imaging modalities to improve diagnostic accuracy and patient outcomes, positioning the US as a leading market for nuclear medicine solutions globally..

Key Market Statistics

  • CAGR (2025-2030) 14.9% CAGR
  • Market Size, 2025 ~USD 4578.4 Million
  • Forecast, 2030 ~USD 9155.5 Million
  • Country US

US Nuclear Medicine Market Overview

Market Valuation Growth :

The US nuclear medicine market is valued at $4,578.4 million in 2025 and is projected to reach $9,155.5 million by 2030, representing a near doubling of market size within five years.

Strong CAGR Performance :

The US market is expanding at a 14.9% CAGR, slightly below the global rate of 15.1%, indicating sustained domestic demand for nuclear imaging and therapeutic solutions across healthcare facilities.

Aging Demographics Driver :

Rising prevalence of chronic diseases combined with an aging US population is accelerating adoption of diagnostic and therapeutic nuclear imaging technologies in clinical practice.

Advanced Healthcare Infrastructure :

The US healthcare system's robust infrastructure and high investment capacity support rapid integration of cutting-edge nuclear medicine technologies and imaging equipment.

US Nuclear Medicine Market Dynamics

  • Healthcare providers across the nation are investing heavily in nuclear imaging infrastructure to meet rising patient demand for early disease detection and personalized treatment options.
  • Technological advancements in imaging resolution and therapeutic applications continue to expand clinical use cases, particularly in oncology, cardiology, and neurology.
  • Reimbursement improvements and regulatory support further strengthen market conditions.
  • The market's expansion reflects broader trends in precision medicine adoption and the US healthcare system's commitment to leveraging molecular imaging for improved patient outcomes and cost-effective care delivery..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • The US nuclear medicine market will grow from $4,578.4M (2025) to $9,155.5M (2030), representing a 14.9% CAGR.
    • Advanced PET and SPECT imaging technologies are driving adoption across US healthcare facilities.
    • The US regulatory framework and strong reimbursement landscape support market expansion through 2030.
    • Aging US population and rising chronic disease prevalence fuel demand for diagnostic and therapeutic nuclear medicine.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    US Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    US: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES345.1393.7449.5513.2585.7668.3762867.814.1
    DIAGNOSTIC & IMAGING CENTERS948.41100.612781484.217231999.523192686.116
    HOSPITALS2062.92363.72709.83106.635604077.946685336.114.5
    OTHER END USERS109.4124.2141.1160.3182206.6234.4265.613.5
    TOTAL3465.83982.24578.45264.26050.86952.47983.59155.514.9

    Target Audience

    • Medical Device Manufacturers : US-based and international manufacturers need precise market sizing and growth forecasts to guide R&D investments, product launches, and commercial expansion strategies in the nuclear medicine sector.
    • Healthcare Facility Operators : Hospital networks, imaging centers, and diagnostic facilities require market intelligence to justify capital expenditures in nuclear medicine equipment and plan service line expansion.
    • Investment & Private Equity Firms : Investors evaluating nuclear medicine companies and healthcare technology portfolios need detailed US market data to assess growth potential, valuation multiples, and exit opportunities.
    • Pharmaceutical & Biotech Companies : Organizations developing radiopharmaceuticals and therapeutic nuclear agents need US market insights to understand demand drivers, clinical adoption rates, and commercialization pathways.
    • Healthcare Consultants & Analysts : Strategy consultants and market research professionals require authoritative US nuclear medicine data to support client advisory work, competitive analysis, and industry benchmarking.

    Reasons to Buy this Report

    • Precise US Market Sizing : Access validated market valuation data specific to the United States, with detailed 2025 baseline ($4,578.4M) and 2030 forecasts ($9,155.5M) to support accurate business planning and investment decisions.
    • Competitive Landscape Intelligence : Understand the US-specific competitive dynamics, market consolidation trends, and key player strategies within the nuclear medicine sector to identify partnership and acquisition opportunities.
    • Demographic & Clinical Insights : Leverage analysis of US aging demographics and chronic disease prevalence patterns to identify high-growth clinical segments and geographic markets with greatest expansion potential.
    • Regulatory & Reimbursement Analysis : Gain insights into US-specific regulatory pathways, FDA approval trends, and Medicare/insurance reimbursement policies that directly impact market adoption and revenue potential.
    • Strategic Growth Planning : Use US market forecasts and CAGR data to develop targeted go-to-market strategies, resource allocation plans, and revenue projections for nuclear medicine products and services.

    Frequently asked questions

    What is the current size of the US nuclear medicine market?

    The US nuclear medicine market is valued at $4,578.4 million in 2025 and is expected to reach $9,155.5 million by 2030.

    What is the projected growth rate for the US nuclear medicine market?

    The US nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2030.

    What factors are driving growth in the US nuclear medicine market?

    Key drivers include technological advancements in PET and SPECT imaging, an aging US population, rising prevalence of chronic diseases, favorable FDA regulations, and strong healthcare reimbursement policies.

    Which imaging modalities dominate the US nuclear medicine market?

    PET (positron emission tomography) and SPECT (single-photon emission computed tomography) systems are the primary imaging modalities driving the US nuclear medicine market, often used in hybrid configurations.

    How does the US nuclear medicine market compare to global trends?

    The US market grows at 14.9% CAGR, slightly below the global rate of 15.1%, reflecting the US market's maturity and the rapid expansion of nuclear medicine in emerging economies.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status